Naurex Raises $38M

Naurex Raises M

Filed under: drug treatment centers in illinois

… including conducting a Phase Ilb trial of GLYX-13, the company's lead NMDA receptor modulator in development for the treatment of depression, advancing its second-generation compound NRX-1074 into Phase I and Il clinical trials in depression and …
Read more on Private Equity Hub (press release)